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ABSTRACT: Protofibrils are transient structures observed during in vitro formation of mature amyloid fibrils
and have been implicated as the toxic species responsible for cell dysfunction and neuronal loss in
Alzheimer’s disease (AD) and other protein aggregation diseases. To better understand the roles of
protofibrils in amyloid assembly and Alzheimer’s disease, we characterized secondary structural features
of these heterogeneous and metastable assembly intermediates. We chromatographically isolated different
size populations of protofibrils from amyloid assembly reactions of Aâ(1-40), both wild type and the
Arctic variant associated with early onset familial AD, and exposed them to hydrogen-deuterium exchange
analysis monitored by mass spectrometry (HX-MS). We show that HX-MS can distinguish among
unstructured monomer, protofibrils, and fibrils by their different protection patterns. We find that about
40% of the backbone amide hydrogens of Aâ protofibrils are highly resistant to exchange with deuterium
even after 2 days of incubation in aqueous deuterated buffer, implying a very stable, presumably H-bonded,
core structure. This is in contrast to mature amyloid fibrils, whose equally stable structure protects about
60% of the backbone amide hydrogens over the same time frame. We also find a surprising degree of
specificity in amyloid assembly, in that wild type Aâ is preferentially excluded from both protofibrils
and fibrils grown from an equimolar mixture of wild type and Arctic mutant peptides. These and other
data are interpreted and discussed in terms of the role of protofibrils in fibril assembly and in disease.
Amyloid fibrils are the primary protein component of
neuritic plaques found in the brains of Alzheimer’s disease
(AD)1 patients and are associated with more than 20 other
amyloid diseases (3). In AD, the amyloid plaques are
composed primarily of the Aâ peptide, a 39-43 residue
proteolytic product of a transmembrane protein called
amyloid precursor protein (APP) (4). All four types of
mutation associated with early onset familial AD are linked
to increased production and/or deposition of Aâ peptides in
the brain (5). Although some studies find that the classically
stained Aâ plaque burden does not correlate perfectly with
AD progression (6), there does appear to be a correlation
between disease and the ratio of soluble to insoluble Aâ in
the brain (7). One attractive hypothesis for resolving the
contrasting genetic and pathological trends is that the toxic
agent in AD is not the extracellular amyloid plaque but rather
another aggregated form of Aâ, possibly a prefibrillar
oligomeric assembly intermediate.
Nonfibrillar oligomeric forms of Aâ clearly exist. Oligo-
meric forms collectively referred to as protofibrils are
typically transiently observed when relatively high, non-
physiological concentrations of monomeric Aâ are incubated
in vitro to generate amyloid fibrils (8, 9). Oligomeric forms
of Aâ have also been characterized in cell cultures (10, 11).
Exogenous and endogenous Aâ protofibrils are cytotoxic (11,
12), a property they share with oligomeric assembly inter-
mediates of other amyloidogenic proteins (13). Striking
evidence in support of a role for protofibrils in AD comes
from a recently described early onset familial AD mutation
in the Aâ peptide itself (E22G) called the Arctic mutation
(14). The Arctic mutation in Aâ (AâARC) has an increased
propensity for forming protofibrils as compared to wild type
Aâ (AâWT), suggesting that this mutation predisposes
individuals to early-onset AD due to the formation of
relatively long-lived, toxic protofibrils (14).
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Recently, Lashuel and co-workers (15) identified condi-
tions that permit the preparation, separation (by size exclusion
chromatography (SEC)), and biophysical characterization of
stable protofibrillar species of Aâ. Under these conditions,
electron microscopic (EM) examination of the protofibrils
formed by Aâ(1-40)ARC revealed several morphologies,
including (a) relatively compact spherical particles roughly
4-5 nm in diameter, (b) annular pore-like protofibrils
(6-9 nm o.d. and 1.5-2 i.d.), (c) large spherical particles
18-25 nm in diameter, and (d) short filaments with chainlike
morphology. Interestingly, protofibrils formed from an equi-
molar mixture of AâWT and AâARC, a biologically relevant
mixture of the two proteins that may model the situation in
heterozygous patients, are more stable than those formed by
AâARC and AâWT alone (15). To better understand their roles
in both assembly of amyloid fibrils and Aâ cytotoxicity, it
is important to further characterize the structural properties
of these protofibrils.
Due to their large size, heterogeneous morphology, and
poor solubility, amyloid fibrils and protofibrils have so far
resisted high-resolution structure determination. The meta-
stability of protofibrils presents an additional impediment.
There are, however, intermediate resolution methods that can
provide insights into the structures of monomers, protofibrils,
and fibrils and to the structural relationships among these
states. In particular, hydrogen-deuterium exchange (HX)
provides significant insight into structure by determining the
pattern and extent of hydrogen bonding within the aggregate
(1). HX methods take advantage of the fact that exchange
of backbone amide protons involved in H-bonded secondary
structures such as R-helices and â-sheets, and/or those buried
in core structure, is substantially slower in comparison to
backbone protons in non-H-bonded regions such as loops
and random coil structures. HX has been widely used in
conjunction with mass spectrometry (MS) to study protein
structure and dynamics (16, 17). HX-MS techniques have
recently been extended to study the structures of amyloid
fibrils (1, 2, 18, 19). Using these methods, we found that
Aâ amyloid fibrils consist of a very rigid core structure, most
likely an H-bonded â-structure, which involves only 19 of
the 39 Aâ backbone amides (1, 2).
In this paper, we extend these methods to characterize the
structure in the soluble oligomeric intermediates formed in
AâARC and mixed AâARC/AâWT fibrillization reactions.
Details of protofibril structure may provide critical insights
into the mechanism of amyloid fibril formation and its role
in the mechanism of pathogenesis as well as the design and
development of AD therapeutics.
MATERIALS AND METHODS
Protofibril Synthesis. Protofibrils were prepared from
chemically synthesized AâWT(1-40) (NH2-DAEFRHDSG-
YEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-COO-
H) and AâARC(1-40 Arctic (E22G)) monomers purchased
as trifluoroacetic acid (TFA) salts from the Biopolymer
Facility at Brigham and Women’s hospital. The detailed
procedure for the preparation of Aâ protofibrils has been
described previously (15). Briefly, lyophilized Aâ monomer
(either Arctic or an equimolar mixture of wt and Arctic) was
dissolved in 1 mM NaOH and then diluted to 100 íM in
0.2  PBS, pH 7.4 followed by incubation at room
temperature for 16-24 h. Large, insoluble particles (consist-
ing of 15-20% of the total Aâ monomer) were removed by
5 min centrifugation at 13 000g and hereafter will be referred
to as pellet. Protofibrils and small soluble Aâ species in the
supernatant were separated using a Superdex 75 HR (Am-
ersham Pharmacia) SEC column equilibrated with 5 mM
Tris-HCl, pH 7.4, 70 mM NaCl. The protein was eluted at
a flow rate of 0.5 mL/min. The size exclusion chromatogram
consisted of a void volume peak corresponding to oligomeric
species of different sizes and morphologies (protofibrils) and
a relatively sharp peak corresponding to species of smaller
hydrodynamic radii, predominantly monomeric Aâ (low
molecular weight; LMW) (15). The presence of small
amounts of rapidly equilibrating oligomers (dimers, trimers,
and tetramers) in the LMW peak cannot be ruled out. The
oligomeric and LMW peaks were split into several fractions
in the order of their elution (PF1-PF3 and LMW1 and
LMW2) and stored at 4 °C. The pellet and the protofibril
fractions were spotted on the grids for EM and also express-
shipped on ice for HX experiments.
Hydrogen Exchange. SEC fractions were stored on ice
after their isolation, and HX experiments were initiated
within 24 h and completed within another 48 h. A 250-500
íL aliquot of protofibril fractions was placed in a YM-10
microcon tube (Millipore) and centrifuged at 14 000g at
3 °C. Since highly concentrated protofibril samples readily
form fibrils, the centrifugation time (30-50 min) was
selected to prevent their concentration on the filter by more
than 5-fold. Each concentrated sample was diluted with D2O
and centrifuged at 3 °C, and the process was repeated one
to two times until the H2O content reached <2%. The filter
was then inverted and centrifuged at 1000g for 3 min to
collect the sample in a fresh centrifuge tube, and the sample
was analyzed for deuterium content after being adjusted to
an equivalent monomer concentration of 15-20 íM. The
average time to prepare each sample was 2.5 ( 0.5 h. This
method of HX sample preparation maintained the integrity
of the protofibril sample while removing salts and introducing
D2O. After HX analysis, samples were held on ice for up to
an additional 24 h and then were analyzed by EM. Impor-
tantly, EMs of the HX analyzed samples confirmed that the
protofibril fractions had not progressed to mature fibrils
during analysis (see Results and Figure 1).
The pellets formed during the preparation of AâARC
protofibrils (after 16 h of incubation at 37 °C) were either
incubated at 37 °C for an additional 24 h to generate mature
fibrils or were stored on ice until HX experiments were
carried out. Pure AâWT (1-40) fibrils were generated by
disaggregating monomer using TFA and hexafluoroisopro-
panol (HFIP) (Pierce) followed by incubation at 37 °C in
1X PBS for 5-7 days (20).
For HX experiments on fibrils and pellets, aggregates were
collected by centrifugation, washed once with 2 mM Tris-
HCl buffer, and resuspended in D-Tris-DCl buffer as
described in detail previously (1). For HX experiments on
monomers, AâARC and AâWT were disaggregated in TFA and
HFIP as stated previously, lyophilized, then dissolved in 2
mM D-Tris-DCl buffer, and immediately analyzed as de-
scribed previously (1).
ESI-MS. The HX equipment and protocol have been
described previously (1, 2). Briefly, the Z electrospray source
of a Quattro II (Micromass) triple quadrupole mass spec-
Accelerated Publications Biochemistry, Vol. 42, No. 48, 2003 14093
trometer was modified with a Valco T union. The sample
solution was infused through one arm of the T where it was
mixed with quenching and dissolving solvent (50:50:0.5 [v/v/
v] H2O/CH3CN/HCOOH) being pumped through the second
arm of the T. The flow rates used for sample and solvent
infusion were 0.5 and 9.5 íL/min, respectively. The mixed
solution was then electrosprayed into the MS using the third
arm of the T. Data were obtained in the multichannel
acquisition mode with mass/charge (m/z) ranging from 650
to 1150 at a rate of 2 s/scan.
Data Analysis. The mass spectra were smoothed using the
Savitzky Golay method implemented in the MassLynx
program (Micromass) and deconvoluted to obtain centroid
and peak area using the Pearson VII equation in PeakFit
(Systat) program. Molecular masses were calculated as
{(m/z)z - [z + (z(%D2O))]} using centroids of the unre-
solved isotopic envelops for the +5 and +6 charge states of
the Aâ peptide as described in detail previously (2). Resulting
mass values derived from both +5 and +6 charge states were
averaged to obtain the molecular masses. The percentage of
D2O in the final solvent mixture being sprayed into the MS
was kept constant at 10% for all the experiments presented
here.
Electron Microscopy. Fibrillar and protofibrillar samples
of Aâ were diluted 2-fold with protein buffer (10 mM Tris-
HCl, pH 7.4, 75 mM NaCl) prior to adsorption to glow-
discharged carbon-coated copper grids. Grids were washed
with four drops of buffer and stained with two drops of
freshly prepared 0.75% uranyl formate (Pfaltz and Bauer,
Waterbury, CT). Specimens were inspected with a Philips
Tecnai 12 electron microscope operated at 120 kV, and
images were taken at a nominal magnification of 52 000
using low dose procedures.
RESULTS
Handling of Aâ Protofibrils. The metastability of Aâ
protofibrils presents particular technical challenges to their
structural analysis. Figure 1 demonstrates that under the
conditions we have developed, there is no significant
difference in the structural properties, as discerned by EM,
of protofibrils before and after HX analysis. In particular,
protofibril preparations post-analysis exhibit no trace of
mature amyloid fibrils.
In previous HX studies of mature fibrils, it was possible
to rapidly remove buffer salts and introduce D2O by
centrifugation (1, 2). However, protofibrils are not pelleted
by low-speed centrifugation, while pelleting of protofibrils
by high-speed centrifugation transforms them into fibrils.
Consequently, a gentler, but also more time-consuming,
ultrafiltration protocol (Materials and Methods) was used to
conduct the buffer exchange of protofibrils. The disadvantage
of this protocol is that early time points (<2 h) of the
exchange kinetics cannot be obtained.
Finally, the lack of stability and heterogeneity of the
protofibril population renders complete correction of the HX
data for artifactual exchange into backbone amide protons
very difficult (2). In the work reported here, therefore,
correction for artifactual exchange is confined to the rapidly
exchanging protons.
HX in AâARC Aggregates. The extent of exchange of
backbone amide protons to deuterons was measured for the
four SEC fractions PF1-PF3 (protofibrils) and LMW1
(monomer rich fraction), plus AâARC monomer and fibrils.
Figure 2A shows representative spectra for each one of these
samples after 2 h of exchange. For reference, the dashed
lines in the top panel correspond to fully protonated, and
fully deuterated, AâARC monomers, the lower and upper mass
limits for this peptide. The m/z ratio measured after HX for
fibrils and fractions PF1-PF3 and LMW1 fall between these
two limits.
Although the HX mass spectrum of fraction LMW1 is
symmetric, suggesting a homogeneous population of mol-
ecules, the mass spectra of fractions PF1-PF3 are broad and
asymmetric (Figure 2A). These qualities are probably due
to the latter fractions being heterogeneous mixtures of
different protofibril structures (ref 15; Figure 1), as well as
the likelihood that fractions PF2 and PF3, due to incomplete
SEC separation, may contain smaller Aâ species. The
asymmetric peaks in the mass spectra of PF1-PF3 could
be reasonably fitted using two peaks, hereafter referred to
as A and B populations, with peak B corresponding to a
more complete incorporation of deuterium. Thus, there are
FIGURE 1: EM of negatively stained images of protofibril fraction
before and after HX experiments. Both images depict samples
obtained from a 1:1 equimolar mixture of AâARC and AâWT
monomer purified on a Superdex 75 SEC column. (A) Freshly
separated protofibril fraction PF2. (B) Same PF2 fraction after HX
experiments. Scale bars are equal to 100 nm.
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at least two distinct molecular environments for Aâ present
in each of the fractions PF1-PF3. These two peaks could
also be due to two different structural states within a
protofibril. For example, the peptide molecules at the ends
of the protofibrils will be expected to exchange more than
those in the inner core structure. This would also be true for
mature amyloid fibrils, but the smaller protofibrils are
expected to contain a larger relative population of surface-
associated monomers and hence possess a much larger
relative population of peak B. Another possibility for the
source of peak B would be the dissociation of protofibrils
into monomers, which are amenable to complete exchange.
The centroids from the deconvoluted peaks were used to
calculate the number of deuteriums exchanged in the two
structural groups in fractions PF1-PF3. These measured
numbers of deuteriums were corrected for rapidly back-
exchanging side-chain and terminal protons (1, 2), and the
corrected data were plotted with respect to HX time (Figure
3A). Data-fitted dashed lines for deuterated AâARC monomer
and deuterated AâWT fibrils are included for reference.2 The
HX into AâARC fibrils clearly overlaps with that in AâWT
fibrils, suggesting that the fibrils of the Arctic mutant are
very similar in structure to those of wild type Aâ. As
previously described for AâWT fibrils (1), the HX pattern
for AâARC fibrils is complex, including a small amount of
material with a deuterium content corresponding to that for
unrestricted exchange into monomeric Aâ (population B in
Figure 2A), in addition to a large amount of material
exhibiting a significant exchange protection (population A
in Figure 2A). To varying degrees, similar complex patterns
are observed in the HX of SEC fractions PF1-PF3 (Figure
2A). In the simplest case, the LMW fraction, consisting of
Aâ species of smaller hydrodynamic radii, exchanges 28
protons in 2 h, with no further exchange with time,
behavior similar to that observed for monomeric Aâ (Figure
3A).
The earlier eluting SEC fractions PF1-PF3 all exhibit both
the A and the B populations characterized by different
degrees of exchange protection. In all three fractions, the B
population exhibits the same amount of exchange, 29
deuteriums. Interestingly, the proportion of population B in
each fraction appears to increase as the hydrodynamic radius
of the fractionating species decreases (Figure 2A). In contrast,
population A in fractions PF1-PF3 (Figure 2A) from the
AâARC assembly is significantly protected from exchange,
incorporating 16 deuteriums by the first time point of 2 h
with a gain of only two more deuteriums over the next 25
h. The metastability of protofibrils raises the possibility that
the exchange protection observed for these fractions might
not be due to the protofibrils themselves but to fibrils that
developed from the protofibrils during the exchange reaction.
However, EM images (Figure 1) clearly show that the
protofibril structure has not changed during the HX experi-
ment.
The data presented above show that mature fibrils, PF1-
PF3, and LMW 1 fractions all exchange differently. Overall,
the amount of exchange into the protected A population of
protons increases as the size decreases. Thus, fibrils exchange
the least, protofibril fractions PF1-PF3 exchange more, and
fraction LMW1 (the last eluting, smallest AâARC species)
exchanges the highest number of protons for deuterons.
Exchange into LMW1 is similar, but not identical, to HX
into monomeric Aâ (the significance of this relatively minor
difference in exchange amplitude needs to be investigated).
Thus, HX-MS can be used to differentiate between monomer,
protofibrils, and fibrils. Further, it appears that protofibrils
contain a very stable core structure, highly resistant to
exchange, just like fibrils (1, 2).
HX in AâWT/AâARC (1:1 Equimolar Mix) Aggregates.
Protofibrils formed from a mixture of AâWT and AâARC are
2 The kinetics data on AâWT fibrils were obtained as described
previously (1) with the exception that the final solvent composition
contained 10% D2O. The completely corrected deuterium content after
140 h of exchange under the conditions used here is 19.3 ( 0.7 as
compared to 20.1 ( 1.4 reported earlier (2).
FIGURE 2: (A) ESI-MS showing +6 charge state of deuterated
AâARC fibrils and deuterated AâARC protofibrils (PF1-PF3) and
LMW fraction after 2 h of incubation in a deuterated buffer. Mass
spectra of protonated and deuterated AâARC monomer are shown
as dashed lines in the top panel for comparison and reference. (B)
ESI-MS showing +6 charge state of deuterated protofibril fractions
and LMW fractions from 1:1 mix of AâARC and AâWT after 2 h of
incubation in a deuterated buffer. Two populations deconvoluted
using curve fitting are labeled as A and B.
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unusually stable, persisting in solution for >60 h as compared
to 24 h for those formed by AâARC alone (15). To analyze
the structures of these stabilized species, soluble oligomers
and LMW species generated from a 1:1 AâWT/AâARC mix
were separated into four SEC fractions, which were then
characterized by HX-MS.
Figure 2B presents representative mass spectra from the
four fractions (PF1, PF2, LMW1, and LMW2) after 2 h
of HX time. Since the molecular weight of AâWT is 72 Da
higher than that of AâARC, peaks of m/z 710-717 correspond
to exchange into AâARC, and peaks of m/z 722-730
correspond to exchange into AâWT. These spectra exhibit a
number of interesting features. First, even though an equimo-
lar ratio of the AâWT and AâARC peptide was used to prepare
the fibrillization reaction, only a very small quantity of AâWT
is present in the oligomeric fractions PF1 and PF2, which
are consequently dominated by the more aggressively amy-
loidogenic AâARC peptide. Correspondingly, smaller species
LMW1 and LMW2 contain primarily AâWT peptide and
relatively little AâARC. As seen for the intermediates in fibril
assembly of AâARC alone (Figure 2A), the mass spectra of
PF1 and PF2 are broad and asymmetric; the unresolved
isotopic envelopes for both AâWT and AâARC peptides are
reasonably fitted using two peaks (labeled as A and B in
Figure 2B), and the centroids of these peaks were used to
calculate the number of deuteriums incorporated.3
Figure 3B presents a plot of a side-chain corrected number
of deuteriums measured in AâWT/AâARC fractions with
respect to HX time. Even though only a very small amount
of AâWT is incorporated into the higher MW fractions, the
amount of exchange into both Arctic and wild type peptides
is essentially equivalent in each fraction. Moreover, the
amount of exchange into these fractions is very similar to
that in the corresponding fractions from AâARC assembly
(Figure 3A). Thus, the population A of fractions PF1 and
PF2 exchanged 17 amide protons after 2 h and only two
more protons over the next 40 h. Exchange into population
B of PF1 and PF2, and in fractions LMW1 and LMW2 as
well, remained constant at 30, the same amount of
exchange that occurs in fresh samples of monomeric Aâ.
The pellets isolated from early time points of the fibril
formation reactions of AâARC alone and the AâARC/AâWT
mixture were also analyzed using HX-MS (Table 1; Figure
3B,C). Interestingly, exchange into this pelleted material is
slightly higher than for mature fibrils but lower than for
protofibrils (Table 1). Thus, these pellets (Figure 3C) appear
3 Multiple peaks may be present for AâARC in fractions PF3 and PF4
and for AâWT in fraction PF1, but the signal-to-noise is very poor for
confident identification and molecular weight determination.
FIGURE 3: (A) Side-chain corrected deuterium content in AâARC
fibrils (blue circles) and fractions PF1 (green diamonds), PF2 (red
squares), PF3 (black triangles), and LMW1 (black squares). (B)
Side-chain corrected deuterium content in AâWT/AâARC pellet (blue
diamonds, AâARC; blue circles, AâWT), protofibril fraction PF1
(green diamonds, AâARC), protofibril fraction PF2 (red diamonds,
AâARC; black circles, AâWT population), LMW1 (black diamonds,
AâARC; red squares, AâWT), and LMW2 (black squares, AâARC;
green triangles, AâWT). The closed and open symbols represent the
deuterium exchange into populations A and B, respectively, from
Figure 2. The top and bottom dashed lines represent the deuterium
level observed for AâARC monomer and AâWT fibrils, respectively.
(C) EM of negatively stained images of AâARC pellet obtained after
16 h of incubation at room temperature. (D) EM of negatively
stained images of AâARC mature fibrils. Scale bars are equal to
100 nm.
Table 1: Summary of the Number of Deuteriums Measured under
the Indicated Conditions
sample
no. of deuteriums
after 2 ( 1 h of
exchange timea
no. of deuteriums
after 24 h of
exchange timea
protected fraction in protofibrils,
population Ab
17.2 ( 0.8 18.1 ( 1.2
exposed fraction in protofibrils,
population Bb
29.6 ( 1.4 29.8 ( 1.9
pellets, population A 13.2 ( 1.2 13.4 ( 1.5
fibrils, population A 9.3 ( 0.5 11 ( 0.4
monomers 30.7 ( 0.6 30.8 ( 0.4
a All values were corrected for fast exchanging side-chain and
terminal protons. b Since exchange into all protofibril fractions is
equivalent (Figure 3), an average value for each sample is reported
here.
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to represent intermediate structures between soluble protofibrils
and mature amyloid fibrils (Figure 3D). EM studies revealed
less ordered fibrillar structures for the pellets relative to
mature fibrils (formed by further incubation of the pellets at
37 °C), which exhibited more extended, and tightly associ-
ated, fibrils. The periodical twisting observed in the mature
fibrils, but not in the pelleted material, is also consistent with
higher ordered fibrillar structures. As seen in all other
oligomeric states described here, these pellets exhibit pro-
tected (peak A) and unprotected (peak B) populations. In
the AâARC/AâWT mixture, 70% of the pelleted AâWT is fully
exchanged within the first hour, suggesting that it is not
incorporated into the growing fibril structure.
DISCUSSION
Understanding the assembly of amyloid fibrils will provide
important insight into human disease. Recreating amyloid
fibril assembly under physiological conditions in vitro and
elucidating the underlying mechanisms, however, also raise
formidable, intriguing challenges. The waxing and waning
of various protofibrillar assemblies in the process of amyloid
fibril formation suggests that these structures may lie on the
pathway for fibril formation and may even be required
intermediates (21). It is also possible, however, that these
structures lie off-pathway, as transient reservoirs for Aâ
molecules that leave, and later re-enter, the productive fibril
formation pathway. Are protofibrils on- or off-pathway
intermediates in amyloid assembly? What is the nature of
protofibril structure, and how does that structure relate to
the structures of mature fibrils? How might the structures
of protofibrils mediate neurodegenerative disease?
The HX data reported here suggest that while protofibrils
possess some degree of stable H-bonded structure; the
amount of that structure is significantly lower than in mature
fibrils (Table 1). The degree of stability of this protected
structure is somewhat surprising. One might have expected
protofibrils to possess no rigid, protective structure at all, at
best perhaps displaying populations of amide hydrogens that
exchange slowly but eventually completely. We find, how-
ever, that protofibrils possess a core structure involving 40%
of the backbone amide protons that are as stably protected
as the amide protons in the highly stable core of mature
amyloid fibrils. Circular dichroism studies on these samples
indicate the presence of â-sheet rich structures (data not
shown), consistent with previous findings (22). Thus, the
most likely source of this highly protective structure is a set
of H-bonds in â-sheet elements within the protofibril. The
impression of incrementally increasing degrees of highly
protective structure, from monomers to protofibrils to fibrils,
is supporting evidence for an on-pathway role for protofibrils
and for the hypothesis that protofibrils possess atomic-level
structural elements that are retained in the mature fibril.
Other HX data presented here support this model. The
progressive increase in the proportion of fully exchanged
population B, as the size of the assemblies decreases from
fibrils to small protofibrils to monomer, also suggests
precursor-product relationships among this series of as-
semblies. Also, the surprising preferential exclusion of AâWT
from the fibril population formed from a 1:1 mix of AâWT
and AâARC is mirrored in the AâWT/AâARC ratios of protofibrils.
The small amount of AâWT present in protofibrils from the
mixed reaction is nonetheless mechanistically important as
suggested by the relative stability of protofibrils from a 1:1
mix reaction (15). Thus, the AâWT population in these
protofibrils is a minor component that nonetheless affects
assembly rates; in essence, AâWT appears to be a competitive
inhibitor of AâARC fibril assembly. AâWT might accomplish
this as a monomer, or as an independent protofibrillar
assembly, that docks to the growing fibril/protofibril but is
incapable of locking into place to propagate the fibril (23,
24). The dramatic preferential incorporation of AâARC
observed in both protofibrils and fibrils in the 1:1 mix
assembly reaction suggests a higher degree of specificity in
amyloid fibril formation than previously suspected and has
general implications for amyloid fibril structure, structural
dynamics, and assembly.
There appear to be at least two general ways in which the
amount of protective H-bonded structure might increase in
the progression of protofibrils to fibrils. One possibility is
that protofibrils possess a similar folded Aâ conformation
to that appearing in fibrils but with fewer of the intermo-
lecular H-bonds seen in the latter; the amount of protective,
internal H-bonding might increase in a kind of global
consolidation of structure underlying the protofibril to fibril
transition. Another possibility is that the internal H-bonded
structure within Aâ in the protofibrils is more or less identical
to that in fibrils and that the increase in total protective
structure observed in the transition is due to new H-bonds
formed at the interfaces between protofibril units when they
assemble into fibrils. These same two possibilities also exist
for the novel, immature fibrils, isolated here from early
assembly time points by centrifugation, which exhibit
protection intermediate between protofibrils and mature
fibrils. These and other open questions about protofibril and
fibril structure and the relationship between them should be
testable by further HX experiments.
There are a number of hypotheses for how aggregates
might be toxic to cells in various amyloid disorders. Some
proposed mechanisms depend on functional activities of
aggregates that one imagines should be associated with
specific structures; among these are the ability to insert into
and depolarize membranes (25) and the ability to specifically
recruit other proteins into the aggregate (26). Other proposed
mechanisms, such as the ability of aggregates to interact with,
and eventually overwhelm, the cellular machinery responsible
for managing misfolded proteins (27), require only that the
structure of the aggregate be non-native. The highly stable
H-bonded core that appears to exist in the protofibril, based
on the HX data presented here, is compatible with toxicity
mechanisms requiring specific functional structures.
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